NCT04959240|Unknown
Expanded Access to Velmanase Alfa
1 other identifier
Velmanase alfa-EAP
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredJul 2021
Brief Summary
Individual patient expanded access requests may be considered for patients who have no other treatment options.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 1, 2021
Completed12 days until next milestone
First Posted
Study publicly available on registry
July 13, 2021
CompletedLast Updated
September 25, 2023
Status Verified
September 1, 2023
First QC Date
July 1, 2021
Last Update Submit
September 22, 2023
Conditions
Interventions
Velmanase AlfaDRUG
Also known as: Lamzede, Lamazym, rhLAMAN, recombinant human alpha-mannosidase
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
alpha-Mannosidosis
Condition Hierarchy (Ancestors)
Mannosidase Deficiency DiseasesCarbohydrate Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesLysosomal Storage DiseasesMetabolic DiseasesNutritional and Metabolic Diseases
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2021
First Posted
July 13, 2021
Last Updated
September 25, 2023
Record last verified: 2023-09